List of Biotech, Pharmaceutical & Life Sciences companies in Finland - 34

Afekta is a metabolomics service provider specialized in microbiota-associated compounds and bioactive phytochemicals present in plant-based foods. They can analyze any biological sample and measure a wide variety of metabolites, with no need to choose a list of compounds in advance!

Aiforia equips pathologists and scientists in preclinical and clinical labs with powerful deep learning artificial intelligence software for translating images into discoveries, decisions, and diagnoses. The cloud based Aiforia products and services aim to escalate the efficiency and precision of medical image analysis, across a variety of fields from oncology to neuroscience and more. From empowering researchers in the identification of novel biomarkers of disease, and supporting R&D scientists in speeding up time-to-market of novel drugs, to helping pathologists enhance the accuracy of cancer diagnostics — Aiforia has the expertise and experience to transform healthcare all the way from discovery to diagnosis.

Aplagon is a clinical stage biopharmaceutical company developing first-in-class therapeutics for thromboinflammatory diseases. These include thrombotic, inflammatory and fibrotic conditions. Aplagon was founded in 2009 and is based on the pioneering research performed by Prof. Riitta Lassila and associates at Wihuri Research Institute in Helsinki, Finland.

Aranda Pharma is a preclinical stage pharmaceutical company. We are developing novel non-steroidal small molecule inhibitors of the androgen receptor, that are advanced as locally acting antiandrogens for the topical treatment of acne and androgenetic alopecia.

Aurealis Therapeutics is a Swiss-Finnish Cell and Gene Therapy Platform Company. Our multi-target cell and gene therapy platform, based on genetically modified safe lactic acid bacteria, addresses unmet medical needs: Chronic Wounds - Diabetic Foot Ulcers, Venous Ulcers, Pressure Ulcers - deadly Cancers - Ovarian Cancer, Peritoneal Carcinomatosis - Inflammation. After successfully completing our Phase 1 clinical study in Diabetic Foot Ulcer (DFU) patients with our lead clinical product AUP-16, our DFU Phase 2 study is ongoing in Italy, Germany and Poland. Venous Ulcers and other ulcers will follow. In Oncology, we are building on impressive pre-clinical data with Oncolytic Bacteria lead candidate AUP-55, which shows increased survival in Ovarian Cancer and peritoneal carcinomatosis. Our pipeline also includes Inflammation, at discovery stage.

Biohit Oyj develops and manufactures diagnostic tests for the early detection of gastrointestinal tract diseases.

Bioretec Ltd. is a medical device company focusing on the development of strong, safe and reliable bioabsorbable and bioresorbable implants for pediatric and adult orthopaedics. Our products are used worldwide, and we continue to further develop materials and products for load-bearing clinical applications.

Bone Index Ltd. is a medical device company with the game-changer point-of-care technology (Bindex®) in osteoporosis screening/diagnostics. The overall aim is to prevent osteoporotic fractures, improve surgical outcomes, and improve the quality of life for families in the United States.

CardioSignal is a health technology company developing groundbreaking solutions for early detection of heart diseases. We are based in Turku, Finland and Palo Alto, CA, United States. The CardioSignal mobile application is a CE-marked class IIa medical device for the detection of atrial fibrillation, available in over 10 countries. The technology we are developing enables a digital cardiac biomarker for other major heart diseases as well. CardioSignal is a brand and a product by Precordior. Originally an academic spinoff, the company’s patented motion sensor technology is built on a decade of research and algorithm development. Our purpose We are supporting healthcare in battling the #1 killer of people in the world. With heart disease numbers only rising, we are facing a health and economic problem described as an epidemic by researchers and physicians around the world. Early identification and treatment of heart disease, such as atrial fibrillation, would help prevent strokes and heart attacks and improve outcomes for individuals and society.

CurifyLabs is a Finnish healthtech company developing solutions for manufacturing personalized medicines in pharmacies and hospitals. CurifyLabs is revolutionizing the way personalized medicines are created. We provide innovative technology that enables the automation of compounding—transforming a traditionally manual, time-intensive process into a streamlined, efficient, and accurate system. The CurifyLabs' Compounding System Solution (CSS) is an automated pharmaceutical compounding platform for non-sterile dosage forms, including tablets, troches, liquids, suppositories, vagitories, ointments and capsules. It enables better treatments for patients and improved efficiency for pharmacies and hospital pharmacies. In addition to cost savings, it ensures high manufacturing standards at the point of care through in-process quality control. The CSS is a user-friendly platform consisting of: GMP manufactured excipient bases, compounding robotics, integrated quality control tools, software and a comprehensive formulation library to meet versatile compounding needs of pharmacies.. CurifyLabs’ CSS technology is currently in use for patients by customers in Europe and US. The CurifyLabs Compounding System Solution offers an easy-to-use, turnkey solution for pharmacists and hospitals, making personalized medication production faster, safer, and more accessible to patients in need. CurifyLabs was founded in 2021 by Charlotta Topelius and Niklas Sandler Topelius.

DelSiTech is a drug delivery and drug development company based in Turku, Finland. DelSiTech has developed a unique proprietary technology making it a world leader in advanced biodegradable silica-based drug delivery. The technology has successfully been applied to the controlled release of small molecules, biopharmaceuticals and viral vectors with a focus on parenteral and local administration. We can work with you from early feasibility testing to clinical proof of concept; the technology can also be licensed to industry partners. With the DelSiTechTMSilica Matrix, we can create novel products, provide alternative administration opportunities, and extend and manage the life cycle of existing products. More patient-friendly products can be developed which release active compounds over days to many months. The technology is also well suited for challenging drug delivery needs such as controlled local delivery to the eye or the brain. At DelSiTech, we are also developing our own in-house supergeneric drug products for significant unmet medical and market needs. Our lead product, 1308, is a 3 month subcutaneous product for hepatitis B. 1308 will enter clinical studies in Q1 2017.

Desentum is a clinical-stage, research-oriented biopharmaceutical company specialized in developing novel types of allergy immunotherapy products (aka allergy vaccines) that are based on switching the immune system's response to allergens from hypersensitivity to tolerance. We have a unique approach for designing allergy vaccines. By studying the molecular mechanism of the hypersensitivity reaction, we have made discoveries that allow for improved design of vaccines against common types of allergies. Our goal is to provide long-term relief from allergic symptoms with only a few months of treatment, as well as reduce the social and economic burden allergies cause to both individuals and society.

Euformatics provides expert computational services at the intersection of life sciences and software. Our mission is to bridge the gap between practicing life scientists and creators of new data analysis and modeling methods, accelerating the transition to precision medicine. Our focus is in adapting cutting-edge research in computational methods and putting them to practice. Our customers are biotech companies and healthcare providers in Finland and abroad.

Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. Its lead program is bexmarilimab, its investigative precision immunotherapy in Phase I/II development as a novel macrophage checkpoint immunotherapy for patients with hematological malignancies. Bexmarilimab is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Faron is based in Turku, Finland and Boston, Massachusetts. Faron is listed on AIM under the ticker ‘FARN’ and Nasdaq First North Growth Market ("Nasdaq First North") under ticker FARON.

Genevia Technologies is a Finnish CRO specialized in delivering diverse bioinformatics solutions. The company was founded in 2011 as a spin-off enterprise by a group of computational systems biology researchers from Tampere University of Technology, in Tampere, Finland. Over a course of 15 years, our team has built up an extensive experience in analyzing and integrating various microarray, next-generation sequencing and proteomics data. We have also been developing and applying systems biological and mathematical modeling techniques on a wide range of applications from bacterial metabolomics to genomics of human cancers. Our mission is to facilitate the use of high-throughput genetic measurements and biological big data in life science companies and research institutions. We provide general genomics and bioinformatics consultation, support in experimental design, acquisition of cost-effective experiments, analysis and integration of data, and design of custom data analysis and visualization pipelines that organizations can use to analyze their data independently. You can find more information about our company, services and customers on our website at http://www.geneviatechnologies.com

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. A Phase 1a clinical trial has demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in humans. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

HVR Cardio is a medical device company focused on developing first-generation transcatheter mitral valve repair solutions. Our minimally invasive technology has the potential to enable safer, faster, and less traumatic cardiac interventions for mitral regurgitation patients worldwide. HVR Cardio's innovative HELIX ring technology has been carefully designed to fit the anatomy of the mitral valve. This allows fast and easy implantation and most importantly, restoration of the valve geometry leading to uncompromised clinical efficacy. With our catheter-based product, we expect to reduce the invasiveness, operation time, and morbidity associated with mitral valve repair operations. This would allow effective treatment of patients at any stage of mitral valve disease, including those who currently have no treatment options. HVR Cardio's patented HELIX ring technology, which is currently at an advanced development stage, can be applied to interventional cardiology as well as to cardiac surgery. Visit hvrcardio.com to learn more.

Scientific Excellence for IVD. With over 30 years of experience Hytest offers antibodies and antigens for improved patient outcomes in such areas as cardiac markers, infectious, neuroscience and autoimmune disease reagents.

LymphaTouch is a pioneering Finnish healthcare technology company manufacturing medical devices for manual therapy and rehabilitation professionals. The patented LymphaTouch technology effectively reduces swelling and mobilizes soft tissue by applying controlled negative pressure and mechanical vibration. LymphaTouch Oy is a ISO13485 certified medical device manufacturer and our products are CE and US FDA registered medical devices.

Mobidiag is a biotechnology company specializing in developing and marketing novel, innovative solutions for molecular diagnostics of infectious diseases.COVID-19: Received Emergency Use Authorization in Finland for its Amplidiag COVID-19 real-time PCR

NADMED Oy is a startup company bringing to market a new accurate high-throughput method to measure NADs from whole blood and other sample matrices.

Nexstim is a Finnish, globally operating medical technology company. Founded in 2000 in Helsinki, Finland, Nexstim is committed to improving the quality of life of patients with significant unmet clinical needs. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders. Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain. SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain. In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on Nasdaq First North Growth Market Finland.

Onego Bio is a US-Finnish food-biotech company revolutionizing the food system by harnessing the power of precision fermentation to manufacture real egg protein entirely animal-free. Their ingredient, Bioalbumen®, sets a new standard for sustainable protein with identical taste and nutrition, superior functional properties and over 90% smaller environmental footprint compared to eggs from chickens. Onego's highly efficient and scalable technology caters to the needs of the food industry searching for stable, sustainable functional ingredients. As a game-changer in the field, the company was selected the Winner of Fast Company's 2023 World Changing Ideas awards and is a co-founder of two industry associations: Precision Fermentation Alliance and Food Fermentation Europe.

Rappta Therapeutics is a late pre-clincal stage biopharmaceutical company We are working on a first-in-class series of anti-cancer molecular glues that reactivate a key tumor suppressor, protein phosphatase 2A (PP2A). Rappta’s proprietary tools and understanding of the target allow us to therapeutically reactivate PP2A, a critical enzyme regulating protein de-phosphorylation and tumor growth. As a result of PP2A’s central role in the regulation of protein phosphorylation, Rappta’s PP2A-reactivating technologies have platform potential for treating a broad range of human diseases.

RNatives is a biotechnology company developing precision RNA-based gene regulating therapies by leveraging its RNAIntelTM platform which identifies small non-coding RNAs that bind directly to gene promoters to regulate gene expression. The Company is developing novel RNA-based therapies to treat ocular, CNS, and metabolic diseases, as well as cancer. The Company's technology is based on years of academic research published by Turunen et al.

Rokote Laboratories Finland Oy is a Finnish vaccine development company. We are developing the Finnish COVID-19 vaccine.

Sooma Oy is developing, manufacturing and marketing a non-invasive therapy devices for neurological and psychiatric disorders (depression and chronic pain). Sooma uses transcranial direct current stimulation (tDCS) technology. Our technology is trusted by over 150 clinics worldwide. We feel that everyone deserves high quality care. With our Sooma therapies, we want to provide an effective and safe way to treat disorders within psychiatry and neurology. We want to offer a safe, drug-free treatment option with minimal side effects, that minimises any discomfort that might otherwise come with treating certain disorders. We want to ensure that medical professionals have access to a treatment option for patients which relieves symptoms without any fear of addiction or dependency. Our mission is to make our therapies an available and accessible option for all who may benefit from them. This includes patients who are unable to visit a clinic, but would benefit from a home-based treatment that does not compromise safety. Our first product is the first portable device approved for treatment of major depressive disorder (MDD). The device is CE-approved and currently marketed in the EU and other markets. Our quality management system has been awarded with ISO 13485:2016 and MDSAP certificates.

StemSight develops off-the-shelf regenerative cell therapies for corneal blindness. Our expertise is in the combination of iPS-derived cells with functional biomaterials - for FASTER tissue regeneration, SAFER cell therapies and EASIER cell delivery.

In many fields of surgery and dentistry, bone has to be cut or removed without damaging the proximal soft structures. Surgify develops new solutions to protect these structures and prevent associated complications. Bleeding, infections and nerve injuries are some of the complications that can severely affect a patients quality of life. Surgify technology improves the safety, speed and precision of bone surgery to minimize these risks.

Tenboron Oy is a biotechnology company based in Finland. Our reason for being is to develop better boron carriers for Boron Neutron Capture Therapy (BNCT).

TILT Biotherapeutics Ltd is a clinical stage company working in oncology towards enabling T-cell therapies and immune checkpoint inhibitors with oncolytic viruses. Embodiments of the technology will be used to enhance tumor infiltrating lymphocytes (TILs), chimeric antigen receptor T cells (CAR T) and immune checkpoint inhibiting antibody therapies. TILT was founded by Pr. Akseli Hemminki, who has published hundreds of papers in the field and treated almost 300 patients with 10 different oncolytic viruses. In 2013, Pr. Hemminki started his second company, TILT Biotherapeutics Ltd, with a technology based on his past findings in the lab, but more importantly in the clinic. The research conducted by TILT alone or in collaboration with some of world’s leading research groups with synergic technologies has generated very excellent results. The lead candidate is a clinical stage TNFα/IL2 armed oncolytic adenovirus (TILT-123 or Ad5/3-E2F-delta24-hTNFα-IRES-hIL2). Multiple Phase I clinical trials are ongoing. For contact: BD (at) tiltbio.com

Three Finnish life science experts have joined forces to form Uniogen, a global pioneer in diagnostic solutions and point-of-care testing. Building on the strong track record of Abacus Diagnostica, Kaivogen and Labrox,

Valo Therapeutics (ValoTx) is a developer of novel immunotherapies in cancer and infectious disease. Our unique approach to immunotherapy, based on oncolytic viruses and viral vectors combined with disease-specific peptides, delivers highly adaptable and immunogenic therapeutic vaccination platforms. A spin-out company from the University of Helsinki, Finland, Valo Tx has assembled a talented team of immunotherapy experts, who together with the founding scientists have the necessary expertise to take its patented technology through clinical development and make it available to patients.

Zora Biosciences Oy is a diagnostics company that identifies markers of disease and develops them into robust high-throughput, value-added clinical methods, with a main focus on cardiovascular disease, offering the CERT - Coronary Event Risk Test.